The US Food and Drug Administration, without being named directly in a presidential memorandum, has been ordered to cease its attempts to secure pre-emptive regulatory authority over the 50 states on safety labeling, including for pharmaceuticals. In addition, the document calls for "heads of departments and agencies [to] review regulations issued within the past 10 years that contain statements in regulatory preambles or codified provisions intended by the department or agency to pre-empt state law, in order to decide whether such statements or provisions are justified under applicable legal principles governing pre-emption."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze